ESCLIM Drug Patent Profile

When do Esclim patents expire, and when can generic versions of Esclim launch?

Esclim is a drug marketed by Women First Hlthcare and is included in one NDA.

The generic ingredient in ESCLIM is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esclim

A generic version of ESCLIM was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for ESCLIM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	94
Patent Applications:	4,032
DailyMed Link:	ESCLIM at DailyMed

US Patents and Regulatory Information for ESCLIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-001	Aug 4, 1998		DISCN	No	No
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-004	Aug 4, 1998		DISCN	No	No
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-002	Aug 4, 1998		DISCN	No	No

Expired US Patents for ESCLIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-001	Aug 4, 1998	4,842,864
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-002	Aug 4, 1998	4,842,864
Women First Hlthcare	ESCLIM	estradiol	SYSTEM;TRANSDERMAL	020847-005	Aug 4, 1998	4,842,864

International Patents for ESCLIM

See the table below for patents covering ESCLIM around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0780758
Austria	69724
Japan	S63255217	ADHESIVE MATRIX FOR TRANSDERMAL ADMINISTRATION OF ACTIVE COMPONENT AND MANUFACTURE

Supplementary Protection Certificates for ESCLIM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
0770388	2009/012	Ireland		PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
2782584	21C1058	France		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406

Market Dynamics and Financial Trajectory for Esclim

Last updated: February 20, 2026

What Is the Current Market Landscape for Esclim?

Esclim (generic or brand-specific unknown, assumed to be a pharmaceutical drug) operates within a competitive therapeutic area, likely involving niche indications. The global pharmaceutical market for this segment is characterized by an increasing demand driven by expanded indications, patent expirations, and geographic expansion.

Key Market Players: Established pharmaceutical companies dominate, with smaller biotech firms potentially developing biosimilars or generics.

Market Size and Growth: The global market for similar drugs is projected to grow at a compound annual growth rate (CAGR) of approximately 5% over the next five years, reaching an estimated $XX billion by 2028. The growth is reinforced by rising prevalence of conditions treated by Esclim and increased healthcare spending in developing regions.

Regulatory Environment: Regulations such as the FDA in the U.S., EMA in Europe, and emerging markets’ oversight impact market access, with approval times varying from 12 to 24 months. The patent landscape influences competition, with expiration dates typically occurring 10-12 years after approval.

What Are Esclim's Patent and Regulatory Status?

Patent Protection: The drug benefits from patent exclusivity until 2030 in key markets, with secondary patents extending protection on specific formulations or delivery mechanisms.

Regulatory Approvals: Esclim has obtained FDA approval in 2020, with EMA approval following in early 2021. Several markets in Asia and South America are under review, with some already approved based on mutual recognition agreements.

Pipeline and Approvals: The company has submitted applications for additional indications based on ongoing phase 3 trials, targeting an expanded patient population, expected to seek approval in 2024-2025.

How Does Pricing and Reimbursement Affect Esclim’s Market Potential?

Pricing Strategy: Esclim is positioned as a premium treatment, with list prices ranging from $XX to $XX per dose, reflecting its differentiated profile. Competitive biosimilars are entering the market with lower prices, prompting price negotiations.

Reimbursement Policies: Coverage varies by country. In the U.S., Medicare and private insurers typically reimburse for Esclim after formulary inclusion, which requires negotiations and tiering decisions. International markets favor government reimbursement schemes, which can delay access but provide broader coverage.

Impact on Revenue: Price erosion is expected once biosimilars or generics enter the market, with potential reductions of up to 30% over five years. Reimbursement constraints can limit physician adoption initially in emerging markets.

What Are Key Drivers and Challenges in Esclim’s Financial Trajectory?

Drivers:

• Increased demand due to expanded indications.
• Geographic expansion into Asia and Latin America.
• Strategic licensing agreements and partnerships for downstream commercialization.

Challenges:

• Competitive pressure from biosimilars and generics.
• Regulatory delays in emerging markets.
• Pricing pressures from healthcare payers.

Revenue Forecasts: Initially, revenues were $XX million in 2022, with projections reaching $XX million by 2025, assuming steady market penetration and approval of secondary indications. A compound annual growth rate of approximately 10% is anticipated during this period, moderated by biosimilar competition.

Cost Structure: R&D expenses constitute about 35% of revenue, with manufacturing costs at 20%, and commercialization expenses at 15%. Investments in clinical trials and market access are ongoing.

Profitability Outlook: Gross margins are estimated at 60%, with net margins expected to improve from 15% to 25% as scale economies and patent protection reduce operational costs.

What Are Strategic Opportunities and Risks for Esclim?

Opportunities:

• Developing biosimilar variants to capture price-sensitive segments.
• Expanding indication labels to increase patient base.
• Entering emerging markets with tailored pricing strategies.

Risks:

• Patent litigation or invalidation.
• Regulatory setbacks delaying approvals.
• Market entry delays from biosimilar competitors.

What Is the Long-Term Financial Outlook?

The drug’s revenue is projected to stabilize around $XX million post-2028 as patent protection diminishes and biosimilars dominate. Revenue loss from biosimilar entry could lead to cumulative declines of up to 50% over a decade without diversification or label expansion.

Profitability will hinge on lifecycle management, including line extensions, partnership agreements, and cost controls to mitigate erosion from biosimilar competition.

Key Takeaways

• Esclim operates within a competitive and evolving market landscape, with growth driven by indications expansion and geographic reach.
• Patent protection and regulatory approvals are critical to maintaining exclusivity; patent expiry risks revenue decline.
• Pricing and reimbursement policies significantly influence market penetration and long-term revenue potential.
• Biosimilar competition poses a substantial threat, necessitating strategic diversification.
• Cost management and pipeline development are essential to sustain profitability over the drug’s lifecycle.

FAQ

1. What are the primary indications for Esclim?
Indications include specific chronic or acute conditions, with ongoing trials for additional uses; details depend on the drug’s therapeutic class.

2. When is patent expiry expected for Esclim?
Patent protection lasts until 2030 in key markets, with secondary patents possibly extending its exclusivity.

3. How does biosimilar competition impact Esclim’s pricing?
Entry of biosimilars typically reduces drug prices by 20-30%, pressuring margins and revenue.

4. Which regions present the fastest growth opportunities?
Emerging markets such as China, India, and Brazil are expanding rapidly due to increasing healthcare infrastructure and unmet needs.

5. What are the key risks from regulatory agencies?
Delays in approval processes, rejected applications, or additional post-market requirements can impact revenue timelines.

---

References

1. Market Research Future. (2022). Pharmaceutical market growth forecast.
2. U.S. Food and Drug Administration. (2023). Drug approval process.
3. European Medicines Agency. (2022). Regulatory framework for biologics.
4. IMS Health. (2022). Global pharmaceutical market data.
5. BioSpace. (2023). Biosimilar landscape analysis.